查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612962

慢性腎臟病市場：按類型、適應症和最終用戶分類 - 全球預測 2025-2030

Chronic Kidney Disease Market by Type (Diagnosis, Treatment), Indication (Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年慢性腎臟病市場價值為1,284.5億美元，預計到2024年將達到1,365.6億美元，複合年成長率為6.50%，到2030年將達到1996.4億美元。

慢性腎臟病(CKD) 是一種以腎功能逐漸喪失為特徵的長期疾病，由於糖尿病和高血壓等因素，影響著全世界數百萬人。 CKD 市場包括藥品、診斷、透析機和腎臟移植，代表了醫療保健領域的巨大需求。 CKD 管理包括早期診斷、監測、治療依從性以及專業診所的諮詢，滿足醫療保健專業人員的需求並改善患者的治療結果。最終用途細分主要集中在醫院、診斷實驗室和研究機構，透過治療和診斷手段的進步推動市場需求。影響 CKD 市場的主要成長要素包括糖尿病和高血壓盛行率的增加、診斷和治療技術的進步以及政府的支持政策。潛在的機會在於個人化醫療和遠端醫療服務的發展，以提供對患者的持續監測。公司應考慮投資人工智慧主導的診斷工具和穿戴式設備，以增強患者的依從性和監測，並有效解決未滿足的臨床需求。然而，市場成長面臨治療成本高、監管挑戰以及患者對早期診斷和治療依從性認知不足等限制。此外，人工智慧、機器學習和區塊鏈等創新技術的整合有可能簡化業務、提高患者診斷準確性並促進安全的患者資料管理。腎臟病學研究和針對 CKD 的先進生物製藥的開發也可能推動業務成長。 CKD 市場是一個高度動態且以消費者為中心的市場，需要不斷創新並適應監管和技術變化。透過跟上這些進步並專注於透過個人化醫療和數位健康解決方案改善患者的治療結果，我們可以顯著提高我們的市場佔有率和盈利。考慮到這些因素，公司需要優先考慮策略聯盟和研究夥伴關係，以有效利用新技術趨勢。

主要市場統計
基準年[2023] 1284.5億美元
預計年份 [2024] 1365.6億美元
預測年份 [2030] 1996.4億美元
複合年成長率（%） 6.50%

市場動態：揭示快速發展的慢性腎臟病市場的關鍵市場洞察

供需的動態交互作用正在改變慢性腎臟病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 隨著人口老化，慢性腎臟病的全球盛行率不斷增加
    • 旨在改善醫療基礎設施的政府和監管支援政策
    • 提高大眾和醫學界對腎臟疾病早期篩檢和診斷的認知
  • 市場限制因素
    • 高成本，各地區產品標準化有差距
  • 市場機會
    • 治療和診斷技術的進步以及產品創新
    • 遠端醫療和遠端監控技術的擴展
  • 市場挑戰
    • 先進腎臟疾病治療商業化的限制

波特五力：駕馭慢性腎臟病市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解慢性腎臟病市場的外部影響

外部宏觀環境因素在塑造慢性腎臟病市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解慢性腎臟病市場的競爭格局

慢性腎臟病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV慢性腎臟病市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估慢性腎臟病市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了慢性腎臟病市場的成功之路

慢性腎臟病市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化，慢性腎臟病的全球盛行率增加
      • 旨在改善醫療基礎設施的政府和監管支援政策
      • 提高大眾和醫學界對腎臟疾病早期篩檢和診斷的認知
    • 抑制因素
      • 高成本，各地區產品標準化有差距
    • 機會
      • 治療診斷技術及產品創新進展
      • 遠端醫療和遠端監控技術的擴展
    • 任務
      • 腎臟疾病進行性治療方法的商業化有限
  • 市場區隔分析
    • 類型：對慢性腎臟病診斷解決方案以確定腎功能的需求不斷增加
    • 最終使用者：醫院和診所提供廣泛的服務，擴大慢性腎臟病治療的範圍。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章慢性腎臟病市場：依類型

  • 診斷
    • 驗血
    • 影像檢查
    • 切片檢查
    • 尿液檢查
  • 治療
    • 透析
    • 腎臟移植
    • 藥物治療
      • ACE抑制劑
      • 血管收縮素受體阻斷劑
      • BETA受體阻斷劑
      • 利尿劑
      • 促紅血球生成素興奮劑
      • Finerenone
      • Glucagon-Like Peptide-1受體促效劑
      • 胰島素
      • Metformin
      • 鉀粘合劑
      • 鈉-葡萄糖共同輸送體-2抑制劑
      • 他汀類藥物

第7章慢性腎臟病市場（按適應症）

  • 慢性間質性腎炎
  • 糖尿病腎臟病
  • 腎絲球腎炎
  • 高血壓腎臟病
  • 阻塞性腎臟病變
  • 多囊腎

第8章慢性腎臟病市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心及實驗室
  • 醫院/診所
  • 專門治療中心

第9章美洲慢性腎臟病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區慢性腎臟病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲慢性腎臟病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Akebia Therapeutics 的 Vafseo 治療 CKD 患者貧血
    • FDA核准慢性腎臟病治療 Jardiance(R)，並指定非建議用途
    • Signify Health 為 Medicare Advantage 會員推出家庭腎臟健康評估
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Allmed Medical Products Co., Ltd.
  • AngioDynamics, Inc.
  • Apotex Inc.
  • Asahi Kasei Corporation
  • AstraZeneca PLC
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Centessa Pharmaceuticals Limited
  • DaVita Inc.
  • Dialife SA
  • Dr. Reddys Laboratories Ltd.
  • Evoqua Water Technologies LLC
  • Fresenius Medical Care AG
  • Galapagos NV
  • Hemoclean Co. Ltd.
  • JMS Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Merck & Co., Inc.
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Rockwell Medical Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Medical Co., Ltd.
  • Trivitron Healthcare
  • XORTX Therapeutics Inc.
Product Code: MRR-99555D550528

The Chronic Kidney Disease Market was valued at USD 128.45 billion in 2023, expected to reach USD 136.56 billion in 2024, and is projected to grow at a CAGR of 6.50%, to USD 199.64 billion by 2030.

Chronic Kidney Disease (CKD) refers to a long-term condition characterized by gradual loss of kidney function, affecting millions globally due to factors such as diabetes and hypertension. The market scope includes pharmaceuticals, diagnostics, dialyzers, and renal transplantation, marking a critical necessity in the healthcare sector. CKD management involves early diagnosis, monitoring, treatment adherence, and consulting specialized clinics, addressing both healthcare providers' needs and enhancing patient outcomes. The end-use segmentation primarily focuses on hospitals, diagnostic laboratories, and research institutes, driving market demand through advancements in therapeutic and diagnostic measures. Key growth factors influencing the CKD market include increasing prevalence of diabetes and hypertension, technological advancements in diagnostic and treatment procedures, and supportive governmental policies. Potential opportunities lie in developing personalized medicine and telehealth services to provide continuous patient monitoring. Companies should consider investments in AI-driven diagnostic tools and wearable devices to enhance patient adherence and monitoring, addressing unmet clinical needs effectively. However, market growth faces limitations such as high treatment costs, regulatory challenges, and inadequate awareness among patients about early diagnosis and treatment adherence. Furthermore, the integration of innovative technologies like AI, machine learning, and blockchain could streamline operations, improve patient diagnosis accuracy, and facilitate secure patient data management. Research into nephrology and development of advanced biopharmaceuticals tailored for CKD can also propel business growth. The CKD market is highly dynamic and consumer-centric, demanding constant innovation and adaptation to regulatory and technological changes. Keeping pace with these advancements and focusing on improving patient outcomes through personalized care and digital health solutions can significantly enhance market presence and profitability. In light of these factors, companies should prioritize strategic collaborations and research partnerships to harness emerging technological trends effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 128.45 billion
Estimated Year [2024] USD 136.56 billion
Forecast Year [2030] USD 199.64 billion
CAGR (%) 6.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Kidney Disease Market

The Chronic Kidney Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing global prevalence of chronic kidney disease with the aging population
    • Supportive government and regulatory policies aimed at improving healthcare infrastructure
    • Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
  • Market Restraints
    • High cost and gap in product standardization across regions
  • Market Opportunities
    • Advancements in treatment and diagnostic technologies and product innovation
    • Expansion of telemedicine and remote monitoring technologies
  • Market Challenges
    • Limited commercialization of advanced kidney disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Kidney Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Kidney Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Kidney Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Kidney Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Kidney Disease Market

A detailed market share analysis in the Chronic Kidney Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Kidney Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Kidney Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Kidney Disease Market

A strategic analysis of the Chronic Kidney Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diagnosis and Treatment. The Diagnosis is further studied across Blood Tests, Imaging Tests, Kidney Biopsy, and Urine Tests. The Treatment is further studied across Dialysis, Kidney Transplant, and Medication. The Medication is further studied across ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Erythropoietin Stimulants, Finerenone, Glucagon-like Peptide-1 Receptor Agonists, Insulin, Metformin, Potassium Binders, Sodium-glucose Cotransporter-2 Inhibitors, and Statins.
  • Based on Indication, market is studied across Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Obstructive Nephropathy, and Polycystic Kidney Disease.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Diagnostic Centers & Laboratories, Hospitals & Clinics, and Speciality Treatment Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
      • 5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
      • 5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and gap in product standardization across regions
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
      • 5.1.3.2. Expansion of telemedicine and remote monitoring technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited commercialization of advanced kidney disease treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
    • 5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Kidney Disease Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Blood Tests
    • 6.2.2. Imaging Tests
    • 6.2.3. Kidney Biopsy
    • 6.2.4. Urine Tests
  • 6.3. Treatment
    • 6.3.1. Dialysis
    • 6.3.2. Kidney Transplant
    • 6.3.3. Medication
      • 6.3.3.1. ACE Inhibitors
      • 6.3.3.2. Angiotensin Receptor Blockers
      • 6.3.3.3. Beta Blockers
      • 6.3.3.4. Diuretics
      • 6.3.3.5. Erythropoietin Stimulants
      • 6.3.3.6. Finerenone
      • 6.3.3.7. Glucagon-like Peptide-1 Receptor Agonists
      • 6.3.3.8. Insulin
      • 6.3.3.9. Metformin
      • 6.3.3.10. Potassium Binders
      • 6.3.3.11. Sodium-glucose Cotransporter-2 Inhibitors
      • 6.3.3.12. Statins

7. Chronic Kidney Disease Market, by Indication

  • 7.1. Introduction
  • 7.2. Chronic Interstitial Nephritis
  • 7.3. Diabetic Nephropathy
  • 7.4. Glomerulonephritis
  • 7.5. Hypertensive Nephropathy
  • 7.6. Obstructive Nephropathy
  • 7.7. Polycystic Kidney Disease

8. Chronic Kidney Disease Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgery Centers
  • 8.3. Diagnostic Centers & Laboratories
  • 8.4. Hospitals & Clinics
  • 8.5. Speciality Treatment Centers

9. Americas Chronic Kidney Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Kidney Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Kidney Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
    • 12.3.2. FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses
    • 12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allmed Medical Products Co., Ltd.
  • 3. AngioDynamics, Inc.
  • 4. Apotex Inc.
  • 5. Asahi Kasei Corporation
  • 6. AstraZeneca PLC
  • 7. B. Braun SE
  • 8. Baxter International, Inc.
  • 9. Becton, Dickinson and Company
  • 10. Centessa Pharmaceuticals Limited
  • 11. DaVita Inc.
  • 12. Dialife SA
  • 13. Dr. Reddys Laboratories Ltd.
  • 14. Evoqua Water Technologies LLC
  • 15. Fresenius Medical Care AG
  • 16. Galapagos NV
  • 17. Hemoclean Co. Ltd.
  • 18. JMS Co., Ltd.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Medtronic PLC
  • 21. Merck & Co., Inc.
  • 22. Nikkiso Co., Ltd.
  • 23. Nipro Corporation
  • 24. Novartis AG
  • 25. NxStage Medical Inc.
  • 26. Otsuka Pharmaceutical Co., Ltd.
  • 27. Reata Pharmaceuticals Inc.
  • 28. Rockwell Medical Inc.
  • 29. Sanofi S.A.
  • 30. Teva Pharmaceutical Industries Ltd.
  • 31. Toray Medical Co., Ltd.
  • 32. Trivitron Healthcare
  • 33. XORTX Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. CHRONIC KIDNEY DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC KIDNEY DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC KIDNEY DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC KIDNEY DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FINERENONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POTASSIUM BINDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CHRONIC INTERSTITIAL NEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLOMERULONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HYPERTENSIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY OBSTRUCTIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SPECIALITY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 269. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 295. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023